What is this Study about?

This study explores Deep Brain Stimulation (DBS) as a potential treatment for mild Alzheimer’s disease (AD). In this study, the mild electrical stimulation is delivered to a part of the brain called the Pedunculopontine Nucleus (PPN), which helps regulate cognitive and sleep-related brain rhythms. The trial will recruit a small group of participants to evaluate the safety, feasibility, and preliminary efficacy of DBS-PPN in treating AD. The goal of this study is to see if targeting this part of the brain with DBS can help people living with mild AD improve their memory, thinking skills, and sleep quality.

What is this Study about?

This study aims to evaluate the acceptance and usability of the GuardIO Family Care app, a mobile application designed to support community safety for individuals living with dementia or mild cognitive impairment and their care partners. The study also aims to analyze mobility patterns collected from the app to explore how mobility data can contribute to the early detection of cognitive impairment. The findings will help improve app design, inform care strategies, and support early intervention efforts for individuals living with dementia or MCI.

What is this Study about?

We are conducting three separate studies to explore the effects of transcranial Direct Current Stimulation (tDCS) in individuals with Alzheimer’s Disease or Primary Progressive Aphasia. tDCS is a non-invasive therapy that uses low electrical currents to stimulate specific areas of the brain. Previous research has suggested that tDCS can improve symptoms such as language difficulties and may help slow the progression of Alzheimer’s.

Our studies aim to investigate these effects in different contexts, including language therapy and overall mental abilities. Upon completion, participants will receive their study results to help guide their decisions about whether tDCS could be part of a long-term therapy plan.

What is this Study about?

The Communication Bridge 3 Study is focused on helping adults with mild to moderate Primary Progressive Aphasia (PPA), a condition that affects language abilities due to neurodegenerative diseases. The study aims to improve functional communication and life participation by providing structured language and communication support remotely through video conferencing.

Participants work with speech-language pathologists to practice communication techniques and learn strategies to address daily communication challenges. The study involves a series of therapy sessions, assessments, and follow-up evaluations to measure changes in communication and participation over time. By tracking participants' progress, the study hopes to identify effective approaches for enhancing quality of life for those living with PPA and their care partners.

What is this Study about?

The aim of this study is to develop a large, ethically sources, and diverse database of voice recordings to determine whether voice has biomarkers for particular disease categories, including neurological and neurodevelopmental conditions. The data that is collected will be used to develop a full open-access database to fuel artificial intelligence research related to voice.

What is this Study about?

It is expected that the information collected during this study will be used in analyses and will be published/presented to the scientific community at meetings and in journals. This information may also be used as part of a submission to regulatory authorities around the world to support the approval of the study intervention for agitation in AD.

What is this Study about?

Our study titled "Investigating the Role of Quantitative Susceptibility Mapping and Oxygen Extraction Fraction as Advanced Neuroimaging Biomarkers in Alzheimer's Disease" aims to develop non-invasive diagnostic biomarkers for Alzheimer's Disease (AD). We focus on evaluating the potential of QSM and OEF to differentiate between AD, Mild Cognitive Impairment (MCI), and Cognitively Unimpaired populations and to predict amyloid and tau pathology, using a Systems Biology approach. Leveraging the McGill University's TRIAD cohort, the study utilizes advanced imaging and machine learning to predict amyloid and tau presence, which could transform AD diagnostics and treatment. Methodologically, it involves preprocessing neuroimaging data and employing machine learning classifiers to analyze these features. The anticipated outcomes include validating QSM and OEF as non-invasive biomarkers for AD, establishing their correlation with amyloid and tau proteins, and developing predictive models for clinical decision-making, potentially resulting in significant advancements in AD diagnostics.